hVIVO (AIM: HVO) wins world-first Phase III whooping cough challenge trial contract with ILiAD Biotechnologies

hVIVO plc (AIM: HVO) has signed a contract with ILiAD Biotechnologies, Inc. to conduct the world’s first pivotal Phase III human challenge trial for BPZE1, a live attenuated intranasal vaccine candidate targeting Bordetella pertussis, the bacterium responsible for whooping cough. The trial, anticipated to enroll more than 500 healthy volunteers, is the largest human challenge trial hVIVO has undertaken to date. Revenue recognition is expected to begin from the first half of 2026, with the majority of contract value flowing through 2026 and 2027. The announcement arrives as hVIVO attempts to rebuild commercial momentum after a revenue contraction year in 2025 and represents a strategically significant step in validating human challenge methodology for pivotal regulatory submissions.

Why does the ILiAD Biotechnologies contract mark a turning point for human challenge trial methodology at regulatory level?

The significance of this contract extends well beyond its revenue contribution. For the first time, a pivotal Phase III efficacy trial for a vaccine will be conducted entirely through a human challenge trial design, with the resulting data intended to support marketing authorisation applications to the United States Food and Drug Administration, the UK Medicines and Healthcare products Regulatory Agency, the European Medicines Agency, and other global regulatory bodies. That is a material shift in how regulators are being invited to treat challenge trial data, which has historically been considered supplementary or hypothesis-generating rather than pivotal.

The practical argument for this design in the pertussis context is compelling. Bordetella pertussis outbreaks are cyclical and unpredictable, occurring without a defined seasonal pattern, which renders conventional field efficacy trials logistically and statistically unreliable. Attempting to power a traditional Phase III study against an endpoint of natural infection would require either enormous participant numbers, prolonged follow-up windows, or the kind of outbreak fortuitousness that no clinical development timeline can be built around. The human challenge model, which guarantees controlled bacterial exposure under supervised quarantine conditions, compresses that uncertainty into a defined and reproducible study design.

Whether regulators agree that this data is sufficient for licensure remains the central open question. The marketing applications are prospective, not approved, and the FDA and EMA retain discretion on whether challenge-derived efficacy data in an adult cohort translates into approval language applicable to the broader populations at risk, including infants under six months, who bear the most severe disease burden. The trial design itself measures colonisation prevention in adults, not disease prevention in vulnerable infants, which may require supplementary data packages before full indications are approved.

How does the global burden of whooping cough justify investment in a next-generation pertussis vaccine?

The epidemiological case for improved pertussis vaccination is not in dispute. Global estimates from peer-reviewed modelling work have placed the annual burden at approximately 24 million cases, with around 160,000 deaths concentrated among young children. Vaccination coverage of approximately 85 percent globally has not translated into sustained community protection, largely because the efficacy of existing acellular pertussis vaccines wanes meaningfully over time, leaving adolescents and adults as persistent reservoirs for transmission to unimmunised or recently born infants.

The UK provides a recent and instructive domestic example. Confirmed pertussis cases in England rose approximately 17 times year-on-year in 2024, a resurgence that illustrated how quickly herd immunity thresholds can erode when waning vaccine protection is combined with a cyclical bacterial rebound. That outbreak context is directly relevant to the commercial and public health positioning of BPZE1.

The ILiAD Biotechnologies vaccine candidate is designed as a needleless intranasal live attenuated product, distinguished from existing Tdap combination vaccines by its administration route and its mechanistic goal of blocking nasal colonisation by Bordetella pertussis rather than merely reducing symptomatic disease severity. If colonisation prevention is validated, the implication is that BPZE1 could interrupt transmission chains, potentially including transmission to vulnerable infants who cannot yet be vaccinated themselves. That is a substantially stronger public health proposition than current vaccines offer, and it is the core of ILiAD Biotechnologies’ regulatory and commercial thesis.

The competitive context is worth noting. Tdap vaccines from Sanofi and GSK currently dominate the pertussis booster market. A next-generation intranasal product with demonstrated colonisation-blocking efficacy in a pivotal study would represent a genuine differentiation on the most commercially important axis, duration and breadth of protection, rather than on incremental immunogenicity improvements.

What does the ILiAD contract mean for hVIVO’s financial recovery trajectory and 2026 revenue guidance?

hVIVO entered 2026 in recovery mode. Full-year 2025 revenue fell to approximately £46.8 million from £62.7 million in 2024, reflecting a wave of human challenge trial cancellations linked to vaccine market volatility and external disruption to the infectious disease research sector, including headwinds from US policy-related changes to funding flows. Adjusted EBITDA recovered to a positive £1.4 million for the year, ahead of prior guidance for a loss, largely on the strength of Q4 operational delivery and contractual protections that generated cancellation fee income. Cash at year-end was approximately £14.3 million with no debt, a balance that reflects both the company’s contractual model and the capital deployed on two acquisitions, the CRS clinical research units in Germany for €10 million and Cryostore for £3.2 million.

Against that backdrop, management has guided for high single-digit revenue growth in 2026, weighted towards the second half of the year. Proposal activity in early 2026 was running approximately 50 percent above the equivalent prior-year period, which provides a credible forward indicator without constituting contractual certainty. The ILiAD Biotechnologies trial is now a concrete revenue line within that guidance framework, with early recognition in the first half of 2026 and the majority of the contract value expected in 2027. That phasing means the contract’s largest financial contribution falls into the next guidance cycle, but its announcement materially de-risks the 2026 pipeline narrative and signals the return of large-scale challenge trial mandates.

The contract is also strategically important because it demonstrates that hVIVO’s bacterial laboratory capability at Canary Wharf, which the company developed in preparation for this study over the preceding twelve months, is now revenue-generating infrastructure rather than a sunk investment. That laboratory will conduct the microbiology assays for the primary and key secondary endpoints of the trial, meaning that the margin profile of this engagement should be meaningful relative to studies where laboratory work is subcontracted or conducted by the sponsor.

How does this contract fit within hVIVO’s wider strategic repositioning away from single-market dependency?

One of the primary analytical threads in hVIVO’s investment case over the past eighteen months has been the company’s acknowledged over-reliance on human challenge trial revenue from the infectious disease and vaccine sector. The 2025 cancellation cycle exposed the fragility of that concentration, and the two acquisitions completed during the year were explicitly framed as mitigation, adding Phase I/II clinical trial site capability, cardiometabolic, immunology, and renal indications, and a broader European geographic footprint.

The ILiAD Biotechnologies contract does not move hVIVO away from human challenge trials. It does the opposite: it reinforces the segment with the company’s largest and most strategically significant HCT mandate to date. That is a coherent strategic choice only if the source of the earlier volatility, which was primarily US funding disruption rather than any structural decline in demand for challenge trial methodology, is treated as cyclical rather than secular. The simultaneous contract win with Traws Pharma for a Phase 2a influenza challenge study, announced days before the ILiAD Biotechnologies news, suggests the order book is rebuilding across both novel and established indications.

The 2026 revenue mix is expected to draw more than 50 percent from non-challenge trial services for the first time in the company’s history, which reflects the acquisitions rather than any retreat from the HCT segment. The challenge trial business is growing back through new contract wins; the non-challenge business is growing through the CRS and Cryostore platforms. If both legs of that structure deliver, hVIVO exits 2027 with a more balanced revenue base and a reset reference case for what the business can earn through a full cycle.

What are the execution and market risks that investors should weigh against the strategic opportunity?

Several risk dimensions merit attention. The regulatory risk associated with pivotal challenge trial data has been discussed above, but the commercial risk for hVIVO is asymmetric: the company earns its fees for conducting the trial irrespective of whether BPZE1 achieves regulatory approval, and the precedent value of a completed pivotal HCT accrues to hVIVO’s competitive positioning regardless of the outcome for ILiAD Biotechnologies.

Execution risk in a 500-participant challenge trial is non-trivial. Participant recruitment at that scale through FluCamp, hVIVO’s in-house database, will need to proceed on schedule to protect the 2026 revenue recognition timeline. Any delays in quarantine throughput, bacterial assay validation issues at the Canary Wharf laboratory, or adverse safety events would affect both the financial trajectory and the reputational significance of the landmark trial. The quarantine facility in London is described as the largest of its kind in the world, but a 500-person trial is a meaningful operational step up from prior studies.

Market perception of hVIVO has been cautious. The stock was trading around 7 to 8.7 pence in mid-April 2026, against a 52-week range of 4.31 pence to 19.50 pence and a consensus analyst price target of approximately 17.69 pence. The year-on-year return has been deeply negative, reflecting the 2025 revenue decline, though the stock showed signs of recovery in the two weeks preceding this announcement. A market capitalisation of roughly £50 to £60 million against trailing revenue of £46.8 million represents a subdued valuation for a business with the pipeline narrative now in place. The ILiAD Biotechnologies contract is the kind of news that could shift the interpretive frame for investors who have been waiting for evidence that the HCT segment can return to growth on a credible basis.

Key takeaways: what does the hVIVO and ILiAD Biotechnologies Phase III whooping cough challenge trial mean for the company, its competitors, and the vaccine industry?

• hVIVO has secured its largest human challenge trial contract to date, with more than 500 participants anticipated across a multi-year engagement that will generate meaningful revenue in both 2026 and 2027.
• The trial is the first pivotal Phase III HCT for Bordetella pertussis globally, and data from it will be submitted directly to the FDA, MHRA, EMA, and other regulators as part of ILiAD Biotechnologies’ marketing authorisation applications for BPZE1.
• A successful regulatory precedent for pivotal Phase III challenge trial data would significantly expand the addressable market for hVIVO’s quarantine and laboratory platform across other indications with unpredictable seasonality or transmission patterns.
• The commercial case for BPZE1 rests on colonisation-blocking efficacy, a materially stronger proposition than existing Tdap vaccines from Sanofi and GSK, which face persistent waning immunity challenges.
• hVIVO’s bacterial laboratory at Canary Wharf, built over the past twelve months specifically in preparation for this trial, will conduct the primary endpoint assays, adding laboratory margin to an already significant contract.
• The announcement provides concrete support for management’s guidance of high single-digit revenue growth in 2026, though the majority of this contract’s value is weighted into 2027.
• hVIVO shares have been trading well below both the 52-week high of 19.50 pence and the analyst consensus target of approximately 17.69 pence, implying that the market had not priced in this contract’s strategic significance ahead of announcement.
• The ILiAD Biotechnologies win, combined with the recent Traws Pharma influenza HCT contract, signals a genuine rebuilding of the challenge trial order book following the 2025 cancellation cycle.
• Execution risk at 500-participant scale through quarantine logistics and bacterial assay delivery remains the primary variable that could affect the revenue recognition timeline.
• For the broader CRO and vaccine development sector, this trial represents a real-world test of whether regulators will accept human challenge trial data as the primary efficacy basis for large-population vaccine approvals, which would reshape development timelines and budgets across the industry.